title: [The effect of celiprolol hydrochloride for lipid metabolism--especially for the low density lipoprotein particle size].
abstract: Recently, much attention has been paid to small sized low density lipoprotein (LDL) as a risk factor for ischemic heart disease. We investigated the effect of celiprolol hydrochloride (CH), which is a beta 1 selective beta-blocker with high intrinsic sympathomimetic activity (ISA), on the LDL particle size. We treated 41 hypertensive patients with CH and studied the change in LDL particle size according to the score of fast beta lipoprotein and LDL relative mobility value (LDL-Rm) measured by lipoprotein polyacrylamide gel disc electrophoresis (PAGE). We also studied changes in blood pressure, total cholesterol (TC), trygiyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and midband on PAGE. Systolic and dyastolic blood pressure and pulse significantly decreased during treatment. TC levels were significantly decreased at 8 weeks in all subjects and at 4, 8 and 12 weeks in patients with a TC value of over 220 mg/dl. TG levels were significantly decreased at 4 and 8 weeks in patients with initial levels of over 150 mg/dl, and significantly increased at 4 and 8 weeks in those with initial levels of under 150 mg/dl of TG. HDL-C levels did not significantly change during treatment. LDL-C levels were significantly decreased at 4, 8 and 12 weeks in patients with initial levels of over 150 mg/dl. Apo AI, AII, B, CII, CIII and E levels did not significantly change during treatment. Fast beta lipoprotein scores did not significantly change overall during treatment, but were significantly decreased at 4 and 8 weeks in patients initial TG levels of over 150 mg/dl and at 4 and 12 weeks in those with initial levels of over 220 mg/dl of TC. LDL-Rm scores did not significantly change during treatment. Midband scores were significantly reduced overall at 8 weeks, and after 4 and 8 weeks in patients with initial TG levels of over 150 mg/dl and at 4, 8 and 12 weeks in those with initial TC levels of over 220 mg/dl. These results indicated that CH did not change LDL particle size. It was suggested that CH might be a beneficial beta-blocker from the standpoint of prevention for atherosclerosis.
authors: Department of Internal Medicine and Clinical Laboratory Medicine, Toho University, Sakura Hospital.
authors: M
authors: M
authors: Totsuka
authors: Y
authors: Y
authors: Miyashita
authors: Y
authors: Y
authors: Ito
authors: T
authors: T
authors: Oyama
authors: S
authors: S
authors: Hashiguti
authors: H
authors: H
authors: Watanabe
authors: K
authors: K
authors: Shirai
authors: T
authors: T
authors: Ban
authors: H
authors: H
authors: Ishihara
authors: K
authors: K
authors: Yamamoto
authors: E
authors: E
authors: Kawano
authors: J
authors: J
authors: Mori
authors: M
authors: M
authors: Kanechi
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight; D017272:Celiprolol / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000097:blood*; D053419:Lipoproteins, IDL; D010316:Particle Size
chemical_list: D000959:Antihypertensive Agents; D008074:Lipoproteins; D053419:Lipoproteins, IDL; D017272:Celiprolol